FDA Clears First Transdermal Patch for Schizophrenia FDA Clears First Transdermal Patch for Schizophrenia

The once-daily transdermal patch provides sustained concentrations of asenapine over 24 hours and is approved for patients with schizophrenia aged 18 and older.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news